Literature DB >> 16731538

Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine.

J W B de Groot, T P Links, W T A van der Graaf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16731538     DOI： 10.1093/annonc/mdl112

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Thyroid dysfunction in patients treated with sunitinib or sorafenib.

Authors:  Julia Clemons; Dexiang Gao; Mary Naam; Kathryn Breaker; David Garfield; Thomas W Flaig
Journal:  Clin Genitourin Cancer       Date:  2012-09-25       Impact factor: 2.872

Review 2.  Thyroid hormone therapy for hypothyroidism.

Authors:  Bernadette Biondi; David S Cooper
Journal:  Endocrine       Date:  2019-08-01       Impact factor: 3.633

Review 3.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

4.  Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database.

Authors:  Takahito Mizuno; Takamasa Sakai; Kouichi Tanabe; Takumi Umemura; Nobuyuki Goto; Fumiko Ohtsu
Journal:  Drugs Real World Outcomes       Date:  2021-03-09

Review 5.  Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.

Authors:  Yi Ling Teo; Han Kiat Ho; Alexandre Chan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 6.  Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

Authors:  Jialu Wu; Hui Huang
Journal:  Drug Des Devel Ther       Date:  2020-09-28       Impact factor: 4.162

7.  The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Authors:  P Wolter; C Stefan; B Decallonne; H Dumez; M Bex; P Carmeliet; P Schöffski
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

8.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

9.  Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors.

Authors:  R Rodia; F Pani; G Caocci; G La Nasa; M P Simula; O Mulas; F Velluzzi; A Loviselli; S Mariotti; F Boi
Journal:  J Endocrinol Invest       Date:  2021-07-20       Impact factor: 4.256
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.